Results 101 to 110 of about 431 (113)

Diversity oriented biosynthesis via accelerated evolution of modular gene clusters. [PDF]

Nat Commun, 2017
Wlodek A, Kendrew SG, Coates NJ, Hold A, Pogwizd J, Rudder S, Sheehan LS, Higginbotham SJ, Stanley-Smith AE, Warneck T, Nur-E-Alam M, Radzom M, Martin CJ, Overvoorde L, Samborskyy M, Alt S, Heine D, Carter GT, Graziani EI, Koehn FE, McDonald L, Alanine A, Rodríguez Sarmiento RM, Chao SK, Ratni H, Steward L, Norville IH, Sarkar-Tyson M, Moss SJ, Leadlay PF, Wilkinson B, Gregory MA.   +31 more
europepmc   +1 more source

Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM. [PDF]

Mult Scler J Exp Transl Clin, 2016
Giovannoni G, Gold R, Kappos L, Arnold DL, Bar-Or A, Marantz JL, Yang M, Lee A.   +7 more
europepmc   +1 more source

Growth-defense trade-offs promote habitat isolation between recently-diverged species. [PDF]

Ecol Evol
Harenčár JG, Salazar-Amoretti D, García-Robledo C, Kay KM.   +3 more
europepmc   +1 more source

Development of a flow cytometry live cell assay for the screening of inhibitors of hepatitis C virus (HCV) replication. [PDF]

Open Virol J, 2012
Garcia-Rivera JA, Lin K, Hopkins S, Gregory MA, Wilkinson B, Gallay PA.   +5 more
europepmc   +1 more source

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. [PDF]

Mult Scler, 2018
Freedman MS, Wolinsky JS, Comi G, Kappos L, Olsson TP, Miller AE, Thangavelu K, Benamor M, Truffinet P, O'Connor PW, TEMSO and TOWER Study Groups.   +10 more
europepmc   +1 more source

Mitochondrial cytopathy with common MELAS mutation presenting as multiple system atrophy mimic. [PDF]

Neurol Genet, 2016
Pröbstel AK, Schaller A, Lieb J, Hench J, Frank S, Fuhr P, Kappos L, Sinnreich M.   +7 more
europepmc   +1 more source

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. [PDF]

Mult Scler, 2019
Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L, RADIANCE Trial Investigators.   +14 more
europepmc   +1 more source

Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. [PDF]

Ther Adv Neurol Disord, 2019
Cohen JA, Tenenbaum N, Bhatt A, Zhang Y, Kappos L.   +4 more
europepmc   +1 more source

Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE. [PDF]

Mult Scler, 2018
Cohan S, Kappos L, Giovannoni G, Wiendl H, Selmaj K, Havrdová EK, Rose J, Greenberg S, Phillips G, Ma W, Wang P, Lima G, Sabatella G.   +12 more
europepmc   +1 more source

Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS. [PDF]

Neurol Neuroimmunol Neuroinflamm, 2015
Zimmermann M, Sanderson NS, Rasenack M, Lalive PH, Lang AB, Curtin F, Lindberg RL, Kappos L, Derfuss T.   +8 more
europepmc   +1 more source